News

With the launch of an adalimumab, Cadila hopes to get a piece of the worldwide biosimilar market for antirheumatic treatments.

To help employers achieve biosimilar savings, the Midwest Business Group on Health has created a 13-step action plan.

Here are the top 5 biosimilar articles for the week of August 24, 2020.

Julianna Merten, PharmD, BCPS, BCOP, of Mayo Clinic provides an overview of growth factor biosimilars for pharmacists amid the pandemic.

Two decades of using anti–tumor necrosis factor (TNF) drugs in inflammatory bowel disease (IBD) have answered some questions and left others unanswered.

The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, chose a leader with a research, public relations, and strategic planning background.

The launch marks the first European market entry for Nepexto.

Opinion leaders discuss the significance of regulatory changes affecting biosimilar and insulin products.

A September 29, 2020, symposium with Sonia T. Oskouei, PharmD, BCMAS, DPLA, of Cardinal Health will explore how to incorporate biosimilars into the treatment of inflammatory conditions.

Celltrion Healthcare said it will begin testing its denosumab (Prolia) biosimilar in a phase 1 clinical trial in September.

The statistics show that for the Rocky Mountain province, biosimilar savings are pouring into the health care system and allowing for significantly greater access.

Two Biogen officials make the case for getting anti–tumor necrosis factor (TNF) biosimilars into wider play.

From China to Taiwan, BeiGene and Bio-Thera Solutions hope to capture a large share of the bevacizumab biosimilar market.

Multiple contenders are lining up for the pending expiration of patents on the blockbuster Regeneron reference product for wet age-related macular degeneration.

Intract Pharma believes infliximab can be delivered orally and, in conjunction with Celltrion Group, aims to apply its technology and expertise to make it happen.

Samsung Biologics said it expects to invest over $2 billion in its new manufacturing plant and bio complex, for which construction will begin later this year.

Express Scripts, the country's largest pharmacy benefit manager, has reshuffled its preferred formulary list for 2021, giving preference to fewer pegfilgrastim products than in 2020.

Here are the top 5 biosimilar articles for the week of August 17, 2020.

The buck stops with the FDA when it comes to approving coronavirus disease 2019 therapeutics applications, said Anand Shah, MD, deputy commissioner for Medical and Scientific Affairs at the FDA.

Samsung Bioepis' latest approval gives it 5 biosimilar approvals in the European marketplace.

After receiving regulatory approval in June, Sandoz launched 2 of its biosimilars on the Canadian market.

Monoclonal antibodies may play a frontline role in dealing with COVID-19 infections, according to Anthony S. Fauci, MD.

US administrative and legislative efforts are moving the United States and Germany more into alignment on drug cost management philosophy, according to a review.

A postmarketing surveillance study of Omnitrope in pediatric patients with growth hormone deficiency sheds new light on how this agent performs relative to its reference product.

Employers could save thousands of dollars by promoting the use of biosimilars that will keep employees with rheumatoid arthritis from having to file for disability, according to Brian Gifford, PhD, research director of the Integrated Benefits Institute.

Ali Mcbride, PharmD, MS, BCOP, is taking a lead role in promoting the use and understanding of biosimilars in oncology.

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Pharmacists in Ireland say the country is losing out on hundreds of millions of dollars in savings owing to the absence of a biosimilar substitution policy.

There has been an outpouring of advocacy tugging biosimilars into the marketplace, and market share of these lower-cost drugs has increased.

Up-and-coming Henlius Biotech consolidates its footing in the biosimilar world with another regulatory approval.